Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ADCT-502

Antibody-drug conjugate · Cytotoxic, directed at HER2 (ERBB2) · developed by ADC Therapeutics

Phase 1 Most advanced trial (none active)

ADCT Developer

1 Registered trials

What is ADCT-502?

ADCT-502 is an antibody-drug conjugate consisting of trastuzumab conjugated to tesirine, a pyrrolobenzodiazepine dimer that causes DNA interstrand cross-links. It targets HER2-expressing cancer cells and is studied in breast cancer, non-small cell lung cancer, gastroesophageal cancer, and bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: HER2 (ERBB2), DNA (secondary target)
Mechanism: Cytotoxic, directed at HER2 (ERBB2)
Pathways: DNA replication inhibition, G2/M cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: ADC Therapeutics S.A. (ADCT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03125200	Phase 1	Breast Cancer	Terminated	ADCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerBreast CancerGastroEsophageal CancerNon Small Cell Lung Cancer

Other drugs acting on ERBB2

Neratinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 ELVN-002 Phase 1 Enozertinib Phase 1/2 NVL-330 Phase 1 TTX-MC138 Phase 1/2 Tuxobertinib Phase 1

More from ADC Therapeutics

Loncastuximab tesirine FDA approved Camidanlumab Tesirine Phase 2 Mipasetamab Uzoptirine Phase 1 Olintatug Tesirine Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADCT page.

Follow ADCT, the company behind ADCT-502

See ADCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADCT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z